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Abstract. The dosimetry for two, similarly sized tumours 
in a lymphoma patient being treated with non-bone mar- 
row ablative, monoclonal antibody therapy is reported. 
The 45-year-old man was infused with 2.48 GBq 
(67 mCi) of !31I-labelled MB-I. Prior to therapy, a time 
series of diagnostic conjugate-view images and a radio- 
nuclide transmission scan were obtained and processed 
to obtain time-activity curves. Starting 2 days after the 
therapeutic infusion of radioactivity, a second conju- 
gate-view time series was obtained. At that time, a quan- 
titative single-photon emission tomography (SPET) ac- 
quisition was also carried out. Pre- and post-therapy 
X-ray computed tomography scans demonstrated a per- 
centage reduction in volume for the right tumour which 
was 3.8 times that for the left tumour. In contrast, diag- 
nostic conjugate views by themselves estimated the ab- 
sorbed dose to be the same for the two tumours. Addi- 
tion of therapy conjugate-view data increased the right- 
over-left ratio but only to 1.22. Normalizing either time- 
activity series by the intra-therapy SPET results in- 
creased the ratio to greater than 1.5. We assume here 
that a differential dose is correct according to the differ- 
ential tumour shirnkage. One can further assume that 
the largest ratio corresponds most certainly to the most 
accurate dosimetric method. Other assumptions are pos- 
sible. While additional study is essential, data from this 
patient suggest that the preferred dosimetric method is 
intra-therapy SPET normalization of either time series. 
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I n t r o d u c t i o n  
Therapy of non-Hodgkin's B-cell lymphoma patients 
with both bone marrow ablative (Press et al. 1989; Eary 
et al. 1990) and non-bone marrow ablative (Wahl et al. 
1990) amounts of 131I-labelled pan B-cell MB-1 mono- 
clonal antibody (Link et al. 1986) is in progress. In both 
of these trials, the patient is initially imaged with conju- 
gate views over days following a diagnostic administra- 
tion of activity for estimation of tumour dosimetry (Eary 
et al. 1989, 1990; Press et al. 1989; Wahl et al. 1990). 
However, one cannot guarantee that the pharmacokinet- 
ics after a therapeutic administration will be the same 
as after tracer administration. Moreover, two phantom 
studies indicate that quantification with single-photon 
emission tomography (SPET) is more accurate than with 
conjugate views (Bigler 1989; Doherty et al. 1985; Zan- 
zonico et al. ] 989). 
For a lymphoma patient, we describe here absorbed- 
dose results for two, similarly sized tumours from the 
predicted therapy time-activity series based on diag- 
nostic conjugate views. We compare them with those 
from (1) that time series with the activities normalized 
by the activities from a single, intra-therapy SPET scan, 
(2) the time series combined with a late-starting therapy 
conjugate-view time series and (3) the series in (2) nor- 
malized by the SPET scan. Another possibility, use of 
SPET during diagnostic scanning, was not attempted 
because of anticipated reconstruction problems with the 
minimal-count data. Note that our basic quantitative 
SPET approach has been validated with an anthropo- 
morphic phantom as being accurate within + 13 % (Kor- 
al et al. 1989). We also measured reduction in volume 
for the two tumours. We then compared the single reduc- 
tion-in-volume ratio to the four calculated radiation ab- 
sorbed-dose ratios. 
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Case report 
The patient studied was a 45-year-old man who was diagnosed 
with advanced-stage, follicular, mixed large and small cell lympho- 
ma and initially treated by splenectomy and chemotherapy consist- 
ing of cyclophosphamide, doxorubicin, vincristine and prednisone. 
His clinical remission lasted about 2 years, at which time wide- 
spread, progressive, bulky lymphadenopathy appeared. A biopsy 
revealed the tumour to be reactive with MB-1, and the patient 
was subsequently referred for entry into a Food and Drug Adminis- 
tration (FDA) and IRB approved study of 131I-labelled MB-I ther- 
apy. 
Diagnosis. After informed consent, quantitative planar imaging of 
the patient using a conjugate-view method was performed at 2, 
24, 48, 72, 96 and 120h post-diagnostic infusion of 185 MBq 
(5 mCi; 40 mg) of 13~I-labetled MB-I. Briefly, the method was 
similar to that of Doherty et al. (1985) and proceeded as follows. 
Two calibration curves were determined. One gave transmission 
versus effective thickness and was obtained with a 57Co disc source 
and a water bath containing various thicknesses of water. The 
other yielded camera efficiency (geometric mean counts/MBq) as 
a function of  effective thickness. It was determined by imaging 
a known activity source of 131I centered in various thicknesses 
of water. A 57Co transmission scan of the patient was taken to 
determine the effective thickness in the region of the tumour. Tu- 
mour regions of interest (ROIs) were drawn on the anterior and 
posterior emission images as well as background ROIs adjacent 
to the tumour. The tumour geometric mean count was obtained 
by subtracting the background and taking the mean. From it and 
the efficiency corresponding to the effective thickness, the value 
for each point on the time-activity curves shown in the top panel 
of Fig. 1 was obtained. 
Therapy. Next, 2 days after the therapeutic infusion of 2.48 GBq 
(67 mCi; 40 mg) of 13~I-labelled MB-I, a therapy conjugate-view 
time series was carried out from 2 to 5 days. At 2 days, a quantita- 
tive SPET acquisition was also made with a GE 400 AT gamma- 
camera plus high-energy collimator, 128 stops and a 21.33-rain 
imaging time. 
To enable SPET Compton scatter correction by the dual-energy 
window method, we employed a 20% photopeak window (nominal 
setting: 327-400 keV) and a scatter window of the same width 
(254-326 keV). Before reconstruction, an approximate correction 
for camera deadtime was also made. For 99mTc we found that 
correction by combining the count rates from the two windows 
and computing a single paralysable model deadtime appears to 
be acceptable (Zasadny et al. 1990). For 131I in a phantom, moni- 
tor-source measurements with the direct window yielded a dead- 
time of 15.0 gs. For the patient, from the direct-window count 
rate and this deadtime, the paralysable model estimated the dead- 
time correction factor to be 1.12. We approximated the desired 
single deadtime correction factor by this value and multiplied both 
projection sets by it. After deadtime correction, the scatter projec- 
tions were subtracted from the photopeak projections using a scat- 
ter multiplier ( " k "  value) of 0.75 (Koral et al. 1990 b). 
The resultant SPET data were reconstructed by an iterative 
expecation maximization (EM) algorithm using an independently 
determined attenuation map and yielding a maximum likelihood 
(ML) solution (Tsui et al. 1989). Convergence of activity values 
is obtained after sixteen iterations of this programme. Attenuation 
maps were extracted from an X-ray computed tomography (CT) 
scan. The technique involves first reconstructing with no attenua- 
tion correction to locate registration landmarks, then superim- 
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Fig. 1. Time-activity curves for two tumors in a lymphoma patient. 
At the top are the results from diagnostic conjugate views along 
with the calculated therapy absorbed dose. At the bottom are the 
corresponding single-photon emission tomography (SPET) activi- 
ties measured during therapy and the results after normalizing the 
diagnostic curves to these values. The new dose is again given. 
The dose difference between the right and left tumor with normal- 
ization agreed better with the post-therapy volume reduction actu- 
ally observed by CT, assuming that absorbed dose is proportional 
to the extent of tumor shrinkage 
posing attenuation maps and finally reconstructing again employ- 
ing attenuation correction based on the maps. The attenuation 
coefficients at each pixel were extrapolated in energy from 70 keV 
(the "effective" energy of the CT scan) to 364 keV (Nickoloff et al. 
1981). The superimposition was achieved by a shifting and scaling 
computer programme which utilized the centers (x, y and z) of 
the two tumours in both modalities as input. One of the resultant 
images is shown in Fig. 2. A needed SPET camera efficiency mea- 
surement for 1311 was made using the method detailed previously 
(Koral et al. 1990a). Absolute tumour activities were then obtained 
from (1) this efficiency and (2) the counts in ROI determined by 
a semi-automated, second-derivative, edge-detection programme. 
The resultant SPET activities in percentage of decay-corrected ad- 
ministered activity for the left and right tumours are shown by 
two points in the bottom panel of Fig. 1. 
Tumour volumes. Initial tumour volumes for dosimetry were deter- 
mined from the CT scan taken 8 days before therapy. The patient 
also had a follow-up CT scan 34 days after therapy, from which 
post-therapy volumes and reductions in volume were calculated. 
Dose calculation. The time-activity data points were fitted by a 
bi-exponential (see curves in top panel of Fig. 1). From this fit, 
the dependence of absolute therapy activity on time was calculated. 
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Fig. 2. One transverse slice from the SPET reconstruction of data 
acquired 48 h after the therapy infusion of 13 lI-labelled monoclon- 
al antibody. A, anterior; P, posterior; L, left; R, right. The "left" 
tumour is to the patient's left at the right side of the picture 
Table 1. Calculated radiation absorbed close as a function of meth- 
od 
Method Left Right Right-over- 
tumour tumour left ratio 
(ay) (ay) 
Diagnostic conjugate 3.30 3.29 1.00 
views 




Combined diagnostic 1.69 2.07 1.22 
and therapy 
conjugate views 
Intra-therapy 2.46 3.80 1.54 
SPET-normalized 
combined diagnostic 
and therapy conjugate 
views 
Integrating the function for this dependence from zero to infinity 
gave the cumulated activity. The SPET-normalized version of a 
curve was obtained by multiplying each activity by a tumour-specif- 
ic constant which is chosen so as to allow the normalized curve 
to pass through the SPET-determined activity. These normalized 
curves are shown in the bottom panel of Fig. 1. (They, of course, 
yielded different cumulated activities.) 
To use the therapy conjugate-view time series, early points had 
to be estimated. These were obtained from the early part of the 
diagnostic series by normalization so that agreement existed at 
day 2 (the start of the therapy series). Then, bi-exponential fitting 
yielded a third set of cumulated activities. The final set was calcu- 
lated by normalizing the combined diagnostic and therapy time 
series by the SPET results. The radiation absorbed self-dose for 
each tumour was found from the respective cumulated activity 
by our implementation of Medical Internal Radiation Dose 
(MIRD) committee methods (Koral et al. 1989). 
Results and discussion 
The pre-treatment volume f rom all pertinent CT slices 
for the right tumour  was 29.6 cm 3 and for the left, 
22.6 cm a. After therapy, the percentage reduction in this 
volume (the ratio of  the difference pre-treatment  volume 
minus post- t reatment  volume over pre-treatment volume 
times 100) was 66.9% for the right and 17.6% for the 
left tumour.  That  is, the percentage reduction for the 
right tumour  was 3.8 times that  for the left. 
Absolute values of  predicted activities were lower 
with therapy conjugate views than with diagnostic ones 
for both  tumours.  As for curve shape, the time to peak 
increased about  53% during therapy compared  with di- 
agnosis for both  tumours.  The activity washed out of  
the right tumour  37% faster during therapy (diagnostic 
time minus therapy time divided by diagnostic time) but 
16% slower for the left ( therapy time minus diagnostic 
time divided by diagnostic time). With therapy conjugate 
views, our time from peak to half-peak for a 40-rag 
protein dose can be compared  with that  for a groin tu- 
mour  with a 55-mg protein dose (Eary et al. 1990). The 
average of  right, 51.3 h, and left, 36.3 h, is 44 h, exactly 
equal to the measurement.  
The effect of  the SPET deadtime correction was to 
increase the calculated activities by 15%. Important ly,  
as seen in Fig. 1, SPET normalization tended to separate 
the time-activity curves pertaining to the left and right 
tumours.  
The resultant radiat ion-absorbed dose values for all 
four procedures are shown in Table 1. It is seen that 
the right-over-left absorbed-dose ratio is 1.00 with di- 
agnostic conjugate views alone. It increases to 1.22 with 
the combinat ion of  diagnostic and therapy conjugate 
views possibly due to differences in pharmacokinetics.  
With intra-therapy SPET normalization of  either of  the 
two, the ratio jumps to greater than 1.5 possibly re- 
flecting increased accuracy with SPET. We assume a 
dose ratio greater than 1.0 is correct because the tumour  
shrinkage ratio is greater than 1.0. The proport ionali ty 
constant of  the assumed relationship between shrinkage 
ratio and dose ratio is not known, however. In addition, 
there are errors in the four calculated dose ratios which 
we assume are somewhat  comparable.  We then tenta- 
tively conclude that  the largest dose ratio corresponds 
most  probably  to the most  accurate dosimetric method:  
intra-therapy SPET normalization of  either conjugate- 
view time series. 
Above, we have assumed that tumour  volume reduc- 
tion serves as a good index of  radiation dose. However, 
tumour  volume regression may not reflect clonogenic 
cell kill, which is presumably coupled to dose. Interphase 
cell killing (of clonogenic and non-clonogenic cells) has 
been adduced as a possible mechanism to explain the 
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apparent cell loss at relatively low radiation dose in lym- 
phoma; the non-clonogenic cell kill may differentially 
affect tumours of the same size, leading to variable cell 
loss and hence volume reduction for the same clonogenic 
cell kill. A superior radiation dose index might be the 
time taken for tumour regrowth (Kallman 1987), but 
it is not available for this patient. 
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